Use of New Bacterial Enzymes to Improve Nitro-Prodrug Cancer Therapy

使用新型细菌酶改善硝基前药癌症治疗

• 批准号: 7371214
• 负责人: AC Matin
• 金额: $ 32.83万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-01-07 至 2010-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7371214
• 关键词: Address; Adverse effects; Affinity; Animals; Antineoplastic Agents; Arts; Attenuated; Autoradiography; Bacteria; Bacterial Genes; Biochemistry; Biology; Biometry; Blood Vessels; CD44 gene; Cancer cell line; Cancerous; Cells; Characteristics; Chemicals; Chemistry; Chemotherapy-Oncologic Procedure; Clinical Trials; Coagulation Process; Collaborations; Critiques; Detection; Dose; Drug Delivery Systems; Drug Kinetics; Drug usage; Effectiveness; Electronic Mail; Enzymes; Evolution; Excision; Fluorescent Probes; Human; Hyaluronan; Hypoxia; Image; Imagery; Imaging technology; In Vitro; Interdisciplinary Study; Investigation; Israel; Killer Cells; Label; Life; Light; Liposomes; Malignant Neoplasms; Metabolic; Methods; Microscopic; Mitomycin; Mus; NAD(P)H dehydrogenase (quinone) 1, human; NQO1 gene; Necrosis; Nitro Compounds; Nitroreductases; Normal Cell; Optics; Penetration; Pharmaceutical Preparations; Pharmacotherapy; Process; Prodrugs; Property; Protein Overexpression; Public Health; Quinones; Salmonella typhimurium; Scientist; Solid; Solid Neoplasm; Staining and Labeling; Staining method; Stains; Suggestion; System; Telephone; Testing; Therapeutic; Toxic effect; Variant; Work; base; benzoquinone; cancer cell; cancer therapy; catalyst; cell killing; chemotherapy; collagenase; cytokine; experience; improved; in vivo; killings; medical schools; molecular imaging; neoplastic cell; novel; phenoxazine; prevent; receptor; restoration; targeted delivery; tumor

DESCRIPTION (provided by applicant): Reductive prodrugs are harmless in their native state but kill both growing and non-growing tumor cells upon reduction. Cancer cure requires selective killing of all cancerous cell with minimal side effects, but this is rarely achieved because most drugs cannot reach all the cells within solid tumors (present in >90% human cancers), and are not selective, being activated also by normal human cells. Thus, a drug/catalyst regime is needed that specifically targets tumors and permits visualization of tumor barriers to drug penetration. This proposal is concerned with a newly discovered nitro-prodrug [6-chloro-9-nitro-5-oxo-5H-benzo[a]phenoxazine (CNOB)] and an evolved high-activity nitroreductase discovered and evolved by the PI. CNOB is an effective drug with the unique quality that its activated product is fluorescent and can be visualized in living animals. Novel methods of drug/catalyst delivery to tumors and removal of tumor barriers are also proposed. Four aims will be pursued. The first two involve in vitro studies: the generality of effectiveness against different cancers, and identification of metabolites. Aim 3 deals with specific delivery of the drug/catalyst to tumors. Hyaluronan-labeled nanoliposomes that target the CD44 receptor over-expressed in nearly all cancers will be used to deliver the drug, the catalyst, or both. However, since some normal cells could also express CD44, harmful non-target delivery could occur. Another approach will therefore also be employed that targets two receptors typically overexpressed in cancer cells. While normal cells may express one of these receptors, they would be highly unlikely to express both. In this approach, CNOB will be delivered by CD44-targeting liposomes, and the catalyst by the cytokine induced killer cells that target the tumor-specific NKG2D receptors. This way the normal cells might receive one or the other component of this therapy (the drug or the catalyst) but not both, thus escaping harm. The pharmacokinetics of the drug will be examined for the delivery methods. Aim 4 will dissect the drug and activated product reach within the tumors and will utilize state of the art microscopic and in vivo imaging technology (confocal, IVIS, intravital, autoradiography of tumor sections) and staining (differential fluorescent labels, staining of blood vessels, regions of hypoxia and necrosis) to detect the tumor regions hindering penetration. Removal of these barriers will be attempted by, for example, use of collagenases to dissolve clots, and restoration of normal vasculature in the tumor. Effective means for treating cancer in mice will result, paving the way for human trials of this exciting new cancer therapy. Relevance to public health. Cancer drugs are often unsatisfactory for two reasons: they also harm the non-cancerous cells; and they fail to kill all the cells within a tumor. The drug under study is harmless to normal cells, and will kill cancer cells because a specially developed enzyme will be delivered specifically only to them. This drug can also be seen inside the body; this will allow detection of penetration barriers within the tumors and their elimination.

描述（由申请人提供）：还原性前药在其天然状态下是无害的，但在还原后杀死生长和非生长的肿瘤细胞。癌症治疗需要以最小的副作用选择性地杀死所有癌细胞，但这很少实现，因为大多数药物不能到达实体瘤（存在于>90%的人类癌症中）内的所有细胞，并且不是选择性的，也被正常人类细胞激活。因此，需要一种药物/催化剂方案，其特异性靶向肿瘤并允许可视化药物渗透的肿瘤屏障。该提议涉及新发现的硝基前药[6-氯-9-硝基-5-氧代-5H-苯并[a]吩恶嗪（hocB）]和由PI发现和进化的进化的高活性硝基还原酶。hocB是一种有效的药物，具有独特的品质，其活化产物是荧光的，并且可以在活体动物中可视化。还提出了将药物/催化剂递送至肿瘤和去除肿瘤屏障的新方法。将实现四个目标。前两项涉及体外研究：对不同癌症的有效性的一般性，以及代谢物的鉴定。目的3涉及药物/催化剂向肿瘤的特异性递送。针对几乎所有癌症中过度表达的CD 44受体的海洛聚南标记的纳米脂质体将用于递送药物、催化剂或两者。然而，由于一些正常细胞也可以表达CD 44，因此可能发生有害的非靶向递送。因此，还将采用靶向通常在癌细胞中过表达的两种受体的另一种方法。虽然正常细胞可能表达这些受体之一，但它们不太可能同时表达两者。在这种方法中，hocB将通过靶向CD 44的脂质体递送，而催化剂将通过靶向肿瘤特异性NKG 2D受体的细胞因子诱导的杀伤细胞递送。通过这种方式，正常细胞可能会接受这种治疗的一种或另一种成分（药物或催化剂），但不会同时接受两种成分，从而逃避伤害。将针对给药方法检查药物的药代动力学。目的4将解剖肿瘤内的药物和活化产物，并将利用最先进的显微镜和体内成像技术（肿瘤切片的共聚焦、IVIS、活体、放射自显影）和染色（差异荧光标记、血管染色、缺氧和坏死区域）检测阻碍渗透的肿瘤区域。将尝试通过例如使用胶原酶溶解凝块和恢复肿瘤中的正常脉管系统来去除这些屏障。将产生治疗小鼠癌症的有效方法，为这种令人兴奋的新癌症疗法的人体试验铺平道路。与公共卫生的相关性。癌症药物通常不令人满意，原因有两个：它们也会伤害非癌细胞;它们不能杀死肿瘤内的所有细胞。研究中的药物对正常细胞无害，并且会杀死癌细胞，因为一种专门开发的酶只会专门针对癌细胞。这种药物也可以在体内看到;这将允许检测肿瘤内的渗透屏障及其消除。